2025-10-05 - Analysis Report
Okay, here's an analysis of Eli Lilly and Co. (LLY) based on the data you provided.  The report is structured with key figures and analysis, followed by a summary.

## Eli Lilly and Co. (LLY) Stock Analysis

**Company Overview:** Eli Lilly and Co. is a global pharmaceutical company that discovers, develops, manufactures, and markets pharmaceutical products.

**1. Performance Relative to S&P 500 (VOO)**

*   **LLY Cumulative Return:** 222.30%
*   **VOO Cumulative Return:** 98.51%
*   **Absolute Spread:** 123.79%
*   **Spread Range (Min-Max):** -33.6 to 248.5
*   **Current Spread:** 115.4
*   **Relative Spread:** 52.8

**Analysis:** LLY has significantly outperformed the S&P 500 (VOO) over the period examined. The relative spread of 52.8 indicates that the current outperformance is positioned around the mid-range of its historical outperformance levels.

**Alpha, Beta, and Financial Metrics (Table Analysis):**

| Year       | CAGR    | MDD      | Alpha   | Beta  | Cap (B) |
|------------|---------|----------|---------|-------|---------|
| 2015-2017  | 11.0%   | 76.1%    | -17.0%  | -0.0  | 75.7    |
| 2016-2018  | 39.0%   | 68.9%    | 24.0%   | -0.0  | 103.7   |
| 2017-2019  | 41.0%   | 68.9%    | 19.0%   | 0.4   | 117.8   |
| 2018-2020  | 34.0%   | 79.8%    | 10.0%   | 0.4   | 151.4   |
| 2019-2021  | 53.0%   | 79.8%    | 7.0%    | 0.5   | 247.6   |
| 2020-2022  | 64.0%   | 79.8%    | 65.0%   | 0.4   | 328.0   |
| 2021-2023  | 125.0%  | 78.9%    | 124.0%  | 0.2   | 522.6   |
| 2022-2024  | 134.0%  | 81.2%    | 113.0%  | 0.2   | 692.1   |
| 2023-2025  | 114.0%  | 83.5%    | 51.0%   | 0.2   | 752.9   |

*   **CAGR (Compound Annual Growth Rate):**  CAGR has consistently been strong, with the most recent periods showing significant growth (above 100%).
*   **MDD (Maximum Drawdown):** The MDD is high, indicating significant price volatility and potential for losses.
*   **Alpha:**  Alpha is generally positive, especially in recent years, demonstrating LLY's ability to generate returns above the market.
*   **Beta:** Beta values are low, suggesting LLY's price is not strongly correlated with the broader market (S&P 500).
*   **Cap (B):** Market capitalization has increased dramatically, reflecting the company's growth and investor confidence.

**2. Recent Stock Price Movement**

*   **Current Price:** 839.87
*   **Previous Close:** 819.85
*   **Change:** 2.44% (Significant positive change indicating a recent upward swing)
*   **5-Day Moving Average:** 795.164
*   **20-Day Moving Average:** 759.9295
*   **60-Day Moving Average:** 744.0788

**Analysis:** The stock price is above all three moving averages, indicating a strong upward trend. The large price increase compared to the previous close suggests positive market sentiment and a possible breakout.

**3. Technical Indicators and Expected Return**

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 71.36 (Approaching overbought territory)
*   **PPO:** 1.23
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (1 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00)
*   **Delta_Previous_Relative_Divergence:** 12.8 (+) (Short-term upward momentum)
*   **Expected Return:** 119.3% (Projected outperformance of S&P 500 over the long term)

**Analysis:**

*   The MRI suggests a favorable investment environment.
*   The RSI indicates that the stock is approaching overbought conditions, which might suggest a potential pullback in the short term.
*   The positive delta of the relative divergence confirms short-term upward momentum.
*   The high expected return suggests substantial long-term potential compared to the S&P 500.
*   The hybrid signal further support to buy.

**4. Recent News & Significant Events (Yahoo Finance)**

*   **Jim Cramer Highlights Eli Lilly’s Drug Potential Beyond Diabetes and Obesity:** Positive coverage emphasizing potential growth drivers beyond current core areas.
*   **Caremark’s New Wegovy Copay Program:** While focused on CVS and Wegovy (Novo Nordisk), this headline impacts the competitive landscape of weight-loss drugs, a key area for LLY.
*   **Novo Nordisk Is Ready for Another Round of the Weight-Loss-Drug Wars:** Directly relevant, indicating intensifying competition in a critical market.
*   **Eli Lilly (LLY) Laps the Stock Market:**  A positive headline indicating strong recent performance compared to the broader market.
*   **US Equity Indexes Rise This Week as AI-Trade Lifts Tech, Healthcare Gains Following Pfizer Deal:** Sector tailwinds benefiting LLY.
*   **5 Large Cap Drug Stocks: Values or Traps?:** Keep an eye on this one, it warrants further investigation to understand if LLY is perceived as a value or a trap.

**Analysis:** Recent news is largely positive, highlighting growth potential, strong performance, and sector tailwinds. However, increased competition in the weight-loss drug market is a factor to watch.

**4-2) Analyst Opinions**

*   **Consensus:** Buy (~1.79)
*   **Target Price (avg/high/low):** 884.48 / 1190.00 / 650.00

**Analysis:** The analyst consensus is "Buy" with an average target price suggesting further upside. However, the wide range of target prices (650.00 to 1190.00) indicates uncertainty in future valuation.

**5. Recent Earnings Analysis**

| 날짜       | EPS   | 매출        |
|------------|-------|-------------|
| 2025-08-07 | 6.3   | 15.56 B$    |
| 2025-05-01 | 3.07  | 12.73 B$    |
| 2024-10-30 | 1.08  | 11.44 B$    |
| 2024-08-08 | 3.29  | 11.30 B$    |
| 2025-08-07 | 3.29  | 11.30 B$    |

**Analysis:**

*   The most recent EPS (6.3) and revenue (15.56 B$) show a significant increase compared to previous quarters, indicating strong financial performance.
*   The discrepancies in the date (2025-08-07) and the values (3.29 / 11.30 B$) need further clarification, as they appear twice.

**6. Financial Information**

| Quarter    | Revenue   | Profit Margin |
|------------|-----------|---------------|
| 2025-06-30 | $15.56B   | 84.27%        |
| 2025-03-31 | $12.73B   | 82.53%        |
| 2024-12-31 | $13.53B   | 82.24%        |
| 2024-09-30 | $11.44B   | 81.02%        |
| 2024-06-30 | $11.30B   | 80.80%        |

| Quarter    | Equity    | ROE      |
|------------|-----------|----------|
| 2025-06-30 | $18.27B   | 30.98%   |
| 2025-03-31 | $15.76B   | 17.50%   |
| 2024-12-31 | $14.19B   | 31.07%   |
| 2024-09-30 | $14.24B   | 6.81%    |
| 2024-06-30 | $13.56B   | 21.88%   |

**Analysis:**

*   **Revenue and Profitability:** Revenue and profit margins have been consistently increasing, demonstrating strong operational efficiency.
*   **Capital and Profitability:** Equity has been growing, and ROE (Return on Equity) is relatively high, indicating effective utilization of shareholder equity.

**7. Overall Summary**

Eli Lilly and Co. (LLY) exhibits strong financial performance, significant outperformance compared to the S&P 500, and positive analyst sentiment. Recent price action suggests upward momentum, supported by encouraging news and financial results. However, the high MDD indicates volatility, and the RSI suggests the stock may be approaching overbought conditions.

**Key Takeaways:**

*   **Strong Growth:**  LLY is experiencing substantial growth in revenue, earnings, and market capitalization.
*   **Outperformance:** It has significantly outperformed the S&P 500 and is expected to continue doing so.
*   **Positive Sentiment:** Analyst ratings and recent news are largely positive.
*   **Potential Risks:** High volatility (MDD), approaching overbought conditions (RSI), and increased competition in the weight-loss drug market are factors to monitor.

**Investment Recommendation:**

Based on the provided data, a buy-and-hold strategy with a long-term investment horizon appears reasonable. However, investors should be aware of the potential for price volatility and closely monitor the competitive landscape and any developments related to the company's pipeline.

***

**Disclaimer:** This analysis is based solely on the provided data and should not be considered financial advice. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.
